Skip to main
Rx MOTS-c

A flat-laid digest of the MOTS-c mitochondrial-derived-peptide literature — every study, dose figure, and access fact set out in order, with the human-data gaps and regulatory status laid bare.

Editorial / About this project

About Rx MOTS-c

The MOTS-c research record laid out as a curated specimen catalogue — honest about where the human evidence stops.

Read the researchContact

What this site is

Rx MOTS-c lays the peer-reviewed MOTS-c literature out the way a catalogue lays out specimens: each study, dose figure, mechanism, and regulatory fact set down as its own labelled entry, cited to source, with equal weight given to what the research establishes and to what it does not. A confirmed preclinical finding and an honest 'no human interventional data' note sit side by side by design.

That cataloguing is the whole function. No clinic stands behind the tray, no clinician is on staff, and nothing here is medical guidance. It manufactures nothing, stocks nothing, and sells nothing.

What the name means

The "Rx" in Rx MOTS-c is editorial framing, not a service claim. It signals that this digest pays close attention to the medicinal and regulatory questions readers actually have — the FDA status, the 503A compounding framework, the anti-doping rules — and lays them out plainly. It does not mean the site prescribes, dispenses, or supplies anything. There is no pharmacy here, no prescriber, and no product.

We name no vendors, clinics, or telehealth providers. Where the regulatory landscape is genuinely in motion — as with the FDA Pharmacy Compounding Advisory Committee's scheduled July 2026 evaluation of MOTS-c — we describe it as exactly what it is: a scheduled discussion, not a decision.

How we handle evidence

Every quantitative claim on this site is tied to a specific published study, listed on the references page with its DOI and PubMed identifier. We distinguish animal and cell findings from human data, and we distinguish observational human biomarker associations from interventional trials — a distinction that matters a great deal for MOTS-c, where the animal evidence is substantial and the human interventional evidence does not yet exist.

We favour the language of the studies themselves: doses are reported as administered to a species by a route, never as recommendations. When the literature is silent, we say so rather than fill the gap. The goal is a record a careful reader can trust and verify against the primary sources.